Arbutus Biopharma (ABUS) has released an update.
Arbutus Biopharma Corporation is set to engage with the investment community by participating in two key investor conferences in Miami, with a presentation at the Barclays Global Healthcare Conference on March 12, 2024. Investors can tune into a live webcast of the event, with a replay available afterwards. The company, known for its work on a potential functional cure for chronic hepatitis B, continues to advance its clinical-stage pipeline, including its RNAi therapeutic and oral PD-L1 inhibitor in ongoing trials.
For further insights into ABUS stock, check out TipRanks’ Stock Analysis page.
